Abstract
Background: Severity of pulmonary thromboembolism (PTE) is related to the determination of early mortality risk rather than distribution and the load of trombus. To determine the risk evaluation biomarkers level have important roles than echocardiography, alternatively.
Aim: Investigation of the effectiveness of biomarkers in the determination of 3 months complicated clinical course (CCC) and mortality, and also acute PTE risk level.
Material and methods: Demographic characteristics, history, clinical findings, risk factors, additional diseases, hemodynamic symptoms of 47 patients (22M, 25F) with objectively documented diagnosis of PTE, were recorded. Before PTE treatment, serum and plasma samples were kept to measure the levels of D-Dimer, cTnT, Mb, NT-ProBNP, HAFBP and GDF-15. Patients were followed for 3 months for complication and mortality.
Results: NT-proBNP levels were similar in submassive and nonmassive groups but they were significantly higher in massive group when compared to other groups (p<0.05). GDF-15 levels were significantly higher in massive group when compared to nonmassive group (p=0.013). Mortality was present in 9 patients.When all the deaths caused are predicted by D-Dimer, HFABP, NT-proBNP and GDF. Deaths caused by PTE were only predicted by D-Dimer, HFABP and GDF-15 levels. NT-proBNP and GDF 15 valuables were predicted the complications (p< 0.05).
Conclusions: This biomarkers used in this study had no significant role in the differentiation of nonmassive and submassive groups. However, NT-proBNP and GDF-15 have been shown that these biomarkers would be beneficial for mortality and CCC, in prediction of 3 months.
- © 2011 ERS
